ライフサイエンスコーパス: platelet count

1 international normalized ratio, fibrinogen, platelet count).

2 phenotypes prompted a revision incorporating platelet count.

3 on levels were significantly associated with platelet count.

4 e, defined as confirmed normalization of the platelet count.

5 y of survival along with multinodularity and platelet count.

6 l and percentage changes in liver volume and platelet count.

7 death and that this influences the neonatal platelet count.

8 volume, hemoglobin level, liver volume, and platelet count.

9 lets daily to maintain a normal steady state platelet count.

10 s not sufficient to completely normalize the platelet count.

11 mild or no bleeding symptoms, regardless of platelet count.

12 notype that is not necessarily correlated to platelet count.

13 bocytopenia, a disorder characterized by low platelet count.

14 patients who require therapy to increase the platelet count.

15 11 or 12) and decreased hemoglobin level and platelet count.

16 ratio of aspartate aminotransferase level to platelet count.

17 rget retaining potential for enhancing human platelet counts.

18 n and function and correlates with increased platelet counts.

19 ccompanied by a transient drop in peripheral platelet counts.

20 many antibody-positive patients have normal platelet counts.

21 riched for platelet function, independent of platelet counts.

22 strated early vascular changes and decreased platelet counts.

23 with severely reduced hemoglobin levels and platelet counts.

24 A is a bleeding tendency, resulting from low platelet counts.

25 ia unless they are bleeding or have very low platelet counts.

26 ing disorder characterized by abnormally low platelet counts.

27 of the underlying disease will also increase platelet counts.

28 ld revise PERSEVERE to incorporate admission platelet counts.

29 C (7.0; P = 0.02), albumin (3.87; P = 0.03), platelet count (1.01; P = 0.02), and steroid use (0.21;

30 load, aspartate aminotransferase levels, and platelet counts; 13 of 106 (12.3%) subjects had TE measu

31 hrombocytopenia (hemoglobin level, 9.4 g/dL; platelet count, 16 x 10(9)/L); these were refractory to

32 est cannot be performed in patients with low platelet counts, 2 new assays were developed to determin

33 dex (2.14 versus 0.74, P = 0.0003) and lower platelet counts (205 versus 293, P = 0.02).

34 bocytopenia aged 1 year to 17 years and mean platelet counts 30 x 10(9)/L or less (mean of two measur

35 absolute neutrophil count (4100/microL), and platelet count (362 x 103/microL) were identified in mod

36 ed placebo, achieved the primary endpoint of platelet count 50 x 10(9) per L or more at least once wi

37 , hypophosphatemia (11 [19%]), and decreased platelet count (8 [14%]).

38 to -1.91%; P = .007), and 41.06% increase in platelet count (95% CI, 23.95%-58.17%; P < .001).

39 cribed coding variants associated with lower platelet count: a common missense variant in CPS1 (rs104

40 ted signal commensurate with the decrease in platelet count after immunodepletion with anti-GPIb or a

41 n this series also demonstrated a decline in platelet counts after stopping heparin, warfarin-associa

42 tifying clinically significant fibrosis, the platelet count, age-platelet index, aspartate aminotrans

43 beta3, myosin IIa, FXIIIa cross-linking, and platelet count all promote 1 or more phases of the clot

44 cause bleeding occurred over a wide range of platelet counts among patients undergoing allogeneic SCT

45 of disorders that are characterized by a low platelet count and are sometimes associated with excessi

46 rity score, Glascow Coma Scale, base excess, platelet count and hemoglobin, adrenaline, and syndecan-

47 ts into TLR7-deficient mice caused a drop in platelet count and increased survival post EMCV infectio

48 s were preferentially male and showed higher platelet count and lower hemoglobin and leukocyte count

49 Platelet count and P-selectin (a ubiquitous cargo of alp

50 o correlation was found between reduction in platelet count and platelet-white blood cell aggregation

51 pleen volume had an inverse correlation with platelet count and prothrombin time but not with serum a

52 level and white blood cell count, and lower platelet count and serum erythropoietin than those with

53 ence of esophageal varices or ascites or low platelet count and splenomegaly.

54 or EX-527 in mice led to a reduction in both platelet count and the number of reticulated platelets.

55 of key coagulation/fibrinolytic proteins and platelet counts and aggregation were similar in wild-typ

56 management of patients with persistently low platelet counts and bleeding.

57 Cdkn2a-deficient strains exhibited increased platelet counts and bone marrow megakaryopoiesis.

58 We compared the platelet counts and clinical correlates of patients with

59 penia, which quickly relapses back to normal platelet counts and deficient plasma VWF.

60 ding substantial decreases in lymphocyte and platelet counts and dysregulation of key biochemical mar

61 dium falciparum monoinfection had the lowest platelet counts and greatest risk of severe thrombocytop

62 l thrombopoietin receptor agonist, increases platelet counts and has preclinical antileukaemic activi

63 Similarly, adult THS exposure also decreased platelet counts and increased neutrophil counts.

64 d that eltrombopag could be used to increase platelet counts and reduce clinically significant bleedi

65 tent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding.

66 penia and is clinically effective in raising platelet counts and reducing bleeding events.

67 LLLT significantly lifted the nadir of platelet counts and restored tail bleeding time when app

68 ed in an aggregometer, which requires normal platelet counts and significant blood sample volumes.

69 with clinically reported measures of patient platelet counts and the severity of thrombocytopenia.

70 , Pf4-Cre(+)-Crry(flox/flox) mice had normal platelet counts and their peripheral platelets were resi

71 There were considerable correlations between platelets count and both of CD62P and MFI.

72 iplasmin, antitrombin, prothrombin time, and platelet count) and the DIC score according the Internat

73 ts (international normalized ratio [INR] and platelet count), and its use may avoid unnecessary blood

74 Hypovolemic shock, high-density lipoprotein, platelet count, and bacterial infection at inclusion are

75 anced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase

76 d active alcoholism (37% versus 10%), higher platelet count, and lower hematocrit at admission in the

77 Age, sex, platelet count, and mean platelet volume were similar be

78 ndomisation was stratified by risk category, platelet count, and region.

79 Mean hemoglobin concentration, platelet count, and spleen and liver volumes remained st

80 measurement [LSM] by transient elastography, platelet count, and spleen diameter with calculation of

81 halomyocarditis virus (EMCV) rapidly reduces platelet count, and this response is attributed to plate

82 ower leukocyte and hemoglobin values, higher platelet counts, and a lower thrombosis risk vs JAK2-mut

83 e bone marrow, completely reconstitute blood platelet counts, and contribute to multiple haematopoiet

84 lung disease, low serum albumin levels, low platelet counts, and high serum levels of alanine aminot

85 od cell parameters but normal neutrophil and platelet counts, and reduced overall survival.

86 -term reduction of peripheral blood cell and platelet counts, and slight anemia.

87 nt; four experienced significantly increased platelet counts, and ten had reduced platelet transfusio

88 .0001), shock (aOR, 3.10; P<.0001), abnormal platelet count (aOR, 2.14; P=.0002), bruising (aOR, 3.17

89 vated GPIIb-IIIa, and CD42b), independent of platelet count, are associated with concurrent bleeding

90 leeding, such as esophageal varices or a low platelet count, are frequently present in these patients

91 model consisted of the baseline albumin and platelet count, as well as the bilirubin, transaminases,

92 tifier [ESDI]) included history of vomiting, platelet count, AST level.

93 e categorized age at 50 and 65 years old and platelet count at 100x10(9)/L and had similar discrimina

94 ndothelium-derived CD105-microparticles, and platelet count at admission could predict the absence of

95 Mean maternal platelet count at birth did not differ between groups (I

96 d cell count, absolute neutrophil count, and platelet count at commonly used thresholds for IBIs.

97 d cell count at least 3 x 10(9) cells per L, platelet count at least 100 x 10(9) platelets per L, and

98 n the MK growth in cultures and the infants' platelet counts at birth.

99 onset (OR 11.27, 95% CI 6.27-20.27), higher platelet counts at presentation (>/=20 x 10(9)/L: OR 2.1

100 (hazard ratio, 1.65; 95% CI, 1.31-2.08 for a platelet count below 50,000/mm3 vs > 150,000/mm3; p < 0.

101 Baseline biopsy stage F3 or F4 and platelet count below normal were the strongest predictor

102 Platelet counts between 6 x 10(9)/L and 80 x 10(9)/L wer

103 P4 deletion resulted in a slight increase in platelet count but had no impact on platelet ultrastruct

104 n ITP, eltrombopag has beneficial effects on platelet count but not platelet activation in the majori

105 spital) showed elevated white blood cell and platelet counts but low hemoglobin and hematocrit levels

106 Dietary ALA increased the platelet count by reducing platelet clearance in the ret

107 telets from healthy donors in vitro, raising platelet counts by 0% (unsupplemented control), 25%, 50%

108 In times of physiological stress, platelet count can transiently rise.

109 unsuitable or unavailable the white cell and platelet counts can be used to determine the likelihood

110 Baseline levels of albumin and platelet counts can be used to guide treatment decisions

111 iance was used to compare the time course of platelet count changes between survivors and nonsurvivor

112 owed a greater and more prolonged decline in platelet counts compared with antibody-negative patients

113 showed higher red cell parameters and lower platelet counts compared with JAK2-V617F;Stat1(+/+) mice

114 ogenase, >/=3 prior treatment lines, and low platelet counts correlating with short survival.

115 etrimental animal physiology was observed as platelet counts, d-dimer, fibrinogen levels, and serum c

116 , haemoglobin decrease not more than 15 g/L, platelet count decrease not more than 25%, spleen volume

117 diarrhoea (eight [13%] vs two [3%]; p=0.05); platelet count decreased (ten [16%] vs four [6%]; p=0.09

118 IPC is the strongest independent platelet count-derived predictor of antiplatelet respons

119 ificant correlation between miRNA levels and platelet counts despite post-thaw processing.

120 ocytopenia (ITP) patients with similarly low platelet counts differ in their tendency to bleed.

121 If the platelet count does not increase after transfusion of 2

122 dian, 6.5) at onset of limb ischemia, rising platelet count during heparin anticoagulation, and plate

123 hat CCL5 signaling through CCR5 may increase platelet counts during physiological stress.

124 logistic model, a history of vomiting, lower platelet count, elevated aspartate aminotransferase (AST

125 edictor of a hypercoagulable TEG profile and platelet count, endotoxin, Protein C and fibrinogen were

126 Nadir platelet counts for most affected neonates occurred at b

127 phase, HCV subtype 1b (vs 1a), and baseline platelet count greater than 100,000/mm(3).

128 ts (61%) showed an overall initial response (platelet count >/=30 x 10(9)/L and >/=2 baseline value).

129 l, 259 patients (85.8%) achieved a response (platelet count >/=50 x 10(9)/L at least once in the abse

130 .2 g/dL (OR, 12.48; 95% CI, 3.86-40.33), and platelet count >10(5) cells/microL (OR, 7.44; 95% CI, 3.

131 he best new expanded classification rule was platelet count >110 x 10(9) cells/L and LSM <25 kPa.

132 can safely avoid screening endoscopy with a platelet count >150 x 10(9) cells/L and a liver stiffnes

133 as achievement of weekly platelet responses (platelet counts >/=50 x 10(9)/L without rescue drug use

134 idence interval [CI], 2.0-4.8) compared with platelet counts >/=81 x 10(9)/L.

135 Platelet count had a biphasic temporal pattern with an i

136 Median platelet count had dropped from 220.5 G/L before extraco

137 omannan value, Karnofsky score, and baseline platelet count had prognostic significance.

138 Platelet counts had a nadir at day 3 followed by a rebou

139 oratory abnormalities such as low sodium and platelet counts had small and subtle differences between

140 azards ratio, 0.98; p = 0.002) and decreased platelet count (hazards ratio, 1.19; p = 0.03) were asso

141 olysis, elevated liver enzyme level, and low platelet count (HELLP) syndrome (3 women had used LMWH);

142 Scale, systolic blood pressure, base excess, platelet count, hemoglobin, prehospital plasma, and preh

143 ucerase enzyme therapy in maintaining stable platelet counts, hemoglobin concentrations, and spleen a

144 an observation time of 12 and 36 months for platelet counts, hemoglobin levels, leukocyte counts (P

145 After adjustment for platelet count, higher levels of thrombin receptor activ

146 hite blood cell count (HR, 1.910; P = .017), platelet count (HR, 7.437; P = .005), and Ph-like ALL (H

147 , but both LSPS and a model combining TE and platelet count identified patients with very low risk (<

148 opag, a thrombopoietic agent, would increase platelet counts, improve platelet activation, and/or red

149 did not improve in 3 WAS/XLT patients whose platelet count improved on eltrombopag.

150 performed a genome-wide association study of platelet count in 12,491 participants of the Hispanic Co

151 trombopag treatment resulted in an increased platelet count in 5 out of 8 patients.

152 ed platelet clearance resulting in increased platelet count in a mouse model of sepsis.

153 the findings for the other groups, the mean platelet count in the 9.3-GBq group decreased chronicall

154 otransferase in two (8%) patients, decreased platelet count in two (8%) patients, and hypophosphataem

155 it levels, white blood cell (WBC) counts and platelet counts in 31,340 individuals genotyped on an ex

156 ically to treat cerebral vasospasm, restored platelet counts in adult mice that were made thrombocyto

157 Hematological analyses indicated a drop in platelet counts in both AGM and marmosets suggestive of

158 tion correlated positively with the neonatal platelet counts in FNAIT, and negatively to the clinical

159 the risk block, and has been associated with platelet counts in humans.

160 An analysis of platelet counts in infants born to mothers following ant

161 s of thrombopoietin-mimetic drugs that raise platelet counts in ITP patients.

162 and hematocrit parameters but increased the platelet counts in Jak2V617F knock-in mice.

163 shorten neonatal platelet survival or reduce platelet counts in newborn mice, indicating the existenc

164 of Hmga2 resulted in increased chimerism and platelet counts in recipients of retrovirally transduced

165 his correlated with normalization of in vivo platelet counts in the transferred SCID mice suggesting

166 Eculizumab resulted in increases in the platelet count; in trial 1, the mean increase in the cou

167 Median platelet counts increased to 50 x 10(9)/L or more by wee

168 The primary end point was the platelet count increment 10 to 90 minutes following tran

169 There was no significant difference in platelet count increment 10 to 90 minutes following tran

170 rom low-responder donors, resulting in lower platelet count increments following transfusion.

171 prognostic significance of elevated immature platelet count (IPC) in patients with coronary artery di

172 hole blood flow cytometry: absolute immature platelet count (IPC), immature platelet fraction, and hi

173 Measuring platelet count is inexpensive and easily feasible for th

174 A low platelet count is often an incidental feature, but it mi

175 Platelet count is the best predictor of the severity of

176 The median number of days with platelet count less than 10 x 10(3)/muL was 3, with medi

177 ive central venous catheter placement with a platelet count less than 20 x 109 cells/L.

178 g major elective nonneuraxial surgery with a platelet count less than 50 x 109 cells/L.

179 g elective diagnostic lumbar puncture with a platelet count less than 50 x 109 cells/L.

180 who had chronic immune thrombocytopenia and platelet counts less than 30 x 10(9) per L were randomly

181 Responses in patients with platelet counts lower than 15 x 10(9)/L, more previous t

182 Rs (leukocyte count < 3.0*10(9)/L or reduced platelet count < 100*10(9)/L) and disease activity (base

183 Thrombocytopenia (platelet count < 150x10(3)/mm(3)), coagulopathy (Interna

184 as aHUS based on the following criteria: (1) platelet count <100 x 10(9)/L, (2) serum creatinine >2.2

185 One patient with cirrhosis (with baseline platelet count <150 000 platelets/microL and albuminemia

186 counts were available, 56 (28%) had a birth platelet count <150 x 10(9)/L and 18 (9%) had platelet c

187 tes (hazard ratio [HR], 2.46; P = 0.031) and platelet count <150,000/muL (HR, 2.37; P = 0.026) were i

188 s; older age (i.e., >65 years), lung cancer, platelet count <20,000/mul, and malignant pericardial fl

189 Bleeding on admission, platelet count <30 < 10(9) /L, fibrinogen level <60 mg/d

190 hy (defined in this study as INR >1.8 and/or platelet count <50 x 10(9) /L) who will be undergoing an

191 cedure-related bleeding that did not vary by platelet count <50,000/mul or >/=50,000/mul (p = 0.1281)

192 Thrombocytopenic mice (platelet counts < 1% of uninfected controls) showed a re

193 In the propensity matched cohort, platelet counts < 50 x 10(9)/L were associated with incr

194 ocytopenia due to bone marrow insufficiency (platelet counts <25 x 10(9) per L) or grade 4 thrombocyt

195 Sepsis patients with platelet counts <50 x 10(9)/L and 50 x 10(9) to 99 x 10(

196 latelet count <150 x 10(9)/L and 18 (9%) had platelet counts <50 x 10(9)/L.

197 trombopag or placebo, stratified by baseline platelet count (<10 x 10(9) platelets per L vs >/=10 x 1

198 R, 1.55; 95% CI, 1.02; 2.36; P = 0.041); low platelet count (<100 Giga/mm(3) : HR, 2.70; 95% CI, 1.62

199 actors independently associated with DC were platelet count (<100 x 10(3) vs >/=100 x 10(3): SHR, 1.8

200 of segments 5-8 versus 4-8; and 4) baseline platelet count (<200 versus >/= 200 Gpt/L).The primary e

201 elet function in patients with extremely low platelet counts (<10(9)).

202 PhtdSer; odds ratio, 1.67; p < 0.01), platelets count (</= 127 g/L; odds ratio, 0.99; p < 0.01

203 nd greatest risk of severe thrombocytopenia (platelet count, <50,000 platelets/microL), compared with

204 awal of antiangiogenic therapy, and lowering platelet counts markedly inhibited tumor rebound after w

205 valence of thromboembolic events and reached platelet count nadir later.

206 Usually, an infant's platelet count normalizes within 2 months.

207 ged lifespan fully accounted for the rise in platelet counts observed during the second week of murin

208 at birth, although for some neonates, nadir platelet counts occurred up to 6 days postnatally.

209 (odds ratio, 0.92; 95% CI, 0.87-0.99), lower platelet count (odds ratio, 0.86; 95% CI, 0.83-0.89), an

210 erval: 0.49, 0.95]; P = .022), and decreased platelet count (odds ratio, 0.99 [95% confidence interva

211 ansfusing hospitalized adult patients with a platelet count of 10 x 109 cells/L or less to reduce the

212 priate for most asymptomatic patients with a platelet count of 20 to 30 x 10(9)/L or higher.

213 /L (reference range, [3.4-9.7] x 10(9)/L), a platelet count of 223 x 10(9)/L (reference range, [158-4

214 une 2011 to have mild thrombocytosis, with a platelet count of 405,000.

215 In November 2011, repeat analysis revealed a platelet count of 433,000, and by February 2012 her plat

216 e was the proportion of patients achieving a platelet count of 50 x 10(9) per L or more at least once

217 cell count of 17000/muL (31% blast cells), a platelet count of 76000/muL, and a hemoglobin level of 1

218 t 1 x 10(3) cells per mm(3) or higher, and a platelet count of 80 000/mm(3) or higher.

219 ravenously once a week until attainment of a platelet count of approximately 250,000 to 300,000 per c

220 tinine clearance of at least 1.0 mL/s, and a platelet count of at least 50 x 10(9) per L.

221 atelet transfusion, symptomatic bleeding, or platelet count of less than 10 x 10(9) per L.

222 ss B disease, age greater than 65 years, and platelet count of less than 150 g/L (P < .003).

223 By multivariate Cox regression, a platelet count of less than or equal to 100,000/mm3 was

224 Patients with a stable platelet count of lower than 30 x 10(9) platelets per L,

225 had a greatly increased risk of bleeding at platelet counts of </=5 x 10(9)/L (odds ratio [OR], 3.1;

226 0 years old, with ALT levels of 40 IU/mL and platelet counts of 100,000, had probabilities of develop

227 albumin level less than 35 g/L and baseline platelet counts of 100,000/mm(3) or less predicted sever

228 ent period, 70 [80%] of 87 patients achieved platelet counts of 50 x 10(9) per L or more at least onc

229 of eltrombopag was effective in maintaining platelet counts of 50 x 10(9)/L or more and reducing ble

230 weekly from 1 mug/kg to 10 mug/kg to target platelet counts of 50-200 x 10(9)/L.

231 ived placebo achieved the primary outcome of platelet counts of at least 50 x 10(9) per L for 6 of th

232 ome was the proportion of patients achieving platelet counts of at least 50 x 10(9) per L in the abse

233 rade 3 or worse haemorrhagic adverse events; platelet counts of less than 10 x 10(9) per L; or platel

234 were ineligible for standard treatments; had platelet counts of less than 30 x 10(9) platelets per L;

235 nt covariates, we investigated the impact of platelet count on 90-day mortality.

236 n against ECM, no significant differences in platelet counts or blood parasitemia levels were observe

237 han 1 (OR, 4.02 [CI, 1.84 to 8.82]), and low platelet count (OR, 1.33 [CI, 1.09 to 1.63] per decrease

238 JAK2 V617F allele burden, white-cell count, platelet count, or clonal dominance.

239 tional status, plasma exchange/infusion use, platelet count, or lactate dehydrogenase or haptoglobin

240 gher in women (P = 0.007) and increased with platelet count (P < 0.0001), whereas it was inversely as

241 nomegaly (P = 0.01) on ultrasound, and lower platelet count (P < 0.001) than those with subclinical P

242 atients with CALR-mutated ET showed a higher platelet count (P = .017) and a lower cumulative inciden

243 tic JAK2 mutation (encoding p.Val617Phe) and platelet count (P = 3.9 x 10(-22)) as well as hemoglobin

244 (P = 0.027), bilirubin (P = 0.005), and low platelet counts (P > 0.0001) were predictive of digestiv

245 n-positive tumors had lower peripheral blood platelet counts (P < .001) and higher D-dimer levels (P

246 while low serum albumin (p = 0.021) and low platelet counts (p = 0.041) predicted AHD.

247 wer HSCs had lower hemoglobin (P = 0.05) and platelet counts (P = 0.05) and showed early graft dysfun

248 acid tests [NAT]), liver function tests, and platelet counts; patient age was also determined.

249 t failure, smoking, hematocrit, and baseline platelet count, patients with an IPC level >/=7,632 plat

250 d 80% (20 mg), vs 0% for placebo, achieved a platelet count (PC) response of >/=50 x 10(9)/L with >/=

251 NLR), platelet-to-lymphocyte ratio (PLR) and platelet count (PC) were shown to be prognostic in sever

252 Platelet counts (PCs) were reduced to less than a median

253 eover, the absence of BAMBI had no effect on platelet counts, platelet activation, aggregation, or pl

254 od counts, specifically with measurements of platelet count (PLT) and mean platelet volume (MPV).

255 ation (MCHC), mean corpuscular volume (MCV), platelet count (PLT) and white blood cell (WBC) count.

256 low-frequency (1% < MAF < 5%) variants with platelet count (PLT), red blood cell indices (MCH and MC

257 level, below-normal white blood cell and/or platelet count, polychemotherapy (vs monotherapy), and r

258 LSM combined with platelet count predicted a risk <5% of VNT in 30% of the

259 To account for baseline differences besides platelet counts, propensity matching was performed, afte

260 efined as an aspartate transaminase level to platelet count ratio index [APRI] of >/=1.5) by IFN-lamb

261 NPMc(+) expression determined a significant platelet count reduction and an expansion of the megakar

262 The most parsimonious model included age, platelet count, requirement for vasopressors, requiremen

263 did the proportion of mothers who achieved a platelet count response (IVIg 38% vs corticosteroids 39%

264 c test, clinicians must rely collectively on platelet count, serum creatinine, and ADAMTS13 activity

265 In an in vivo murine acute colitis model, platelet count significantly correlated with inflammatio

266 Longitudinally, mean platelet counts significantly declined in the CFLD group

267 (hemolysis, elevated liver enzymes, and low platelet count) syndrome are pregnancy-related complicat

268 However, despite having significantly higher platelet counts than controls, these mice showed severel

269 gher fibrinogen but lower d-dimer levels and platelet counts than drowning patients (p<0.001).

270 Deceased CFLD patients had lower platelet counts than those alive with CFLD (143 versus 2

271 Patients with retinal hemorrhages had lower platelet counts than those without (median, 22 vs 43 x 1

272 treated with an Ezh2 inhibitor showed higher platelet counts than vehicle controls.

273 on international normalized ratio (INR) and platelet counts that triggered the perioperative utiliza

274 infections have been associated with reduced platelet counts, the biological significance of which ha

275 ion of blood volume expansion and increasing platelet counts, the platelet mass increased sevenfold d

276 esponsive to the agonists independently from platelet count; this phenomenon was blunted by incubatio

277 tansine plus pertuzumab group were decreased platelet count (three [1%] of 223 patients vs 11 [5%] of

278 omboplastin time (four [10%]), and decreased platelet count (three [7%]) in the bone sarcoma group, a

279 Maintaining a higher platelet count threshold (</=20 x 109/L or </=30 x 109/L

280 What is the optimal platelet count threshold for prophylactic platelet trans

281 Prophylactic platelet transfusion at defined platelet count thresholds is still recommended for pedia

282 opoiesis was determined by quantification of platelet counts, thrombopoietin, immature platelet fract

283 n of ribavirin therapy and the return of the platelet count to a normal level.

284 Comparison of platelet count trends revealed that there was no statist

285 Using platelet count trends to guide decision to test for hepa

286 induced thrombocytopenia testing results and platelet count variables were obtained from the electron

287 sepsis patients were stratified according to platelet counts (very low <50 x 10(9)/L, intermediate-lo

288 t count of 433,000, and by February 2012 her platelet count was 509,000.

289 cytes were detected in the peripheral smear, platelet count was 60,000 cells per mm(3), and serum glu

290 Although a significant recovery of the platelet count was observed in survivors, a recovery did

291 The platelet count was significantly decreased in HCV and/or

292 the intensive care unit, and fibrinogen and platelet count were identified as the best routine coagu

293 lpha-fetoprotein, up-to-7 criteria, TTV, and platelet count were predictors of successful downstaging

294 of C-reactive protein, body mass index, and platelet count were used to develop the COPPS system.

295 al hemorrhage was noted in 2 neonates (nadir platelet counts were 135 and 18 x 10(9)/L).

296 Of 203 neonates in whom platelet counts were available, 56 (28%) had a birth pla

297 diagnosis, the longer it took before stable platelet counts were reached.

298 her, while hematocrit, mean cell volume, and platelet counts were significantly lower compared to con

299 suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be mark

300 mpared to SOC (transfusion guided by INR and platelet count), without an increase in bleeding complic